Table IV.
Multivariate analysis of clinicopathological features, miR-130a, miR-25 and miR-191* expression and prognosis of patients with non-small cell lung cancer.
| 95% CI of Exp(B) | |||||||
|---|---|---|---|---|---|---|---|
| Factor | B | SE | Wald | P-value | Exp(B) | Lower | Upper |
| Age (<60 years vs. ≥60 years) | −0.093 | 0.338 | 0.075 | 0.784 | 0.912 | 0.470 | 1.767 |
| Sex (male vs. female) | −0.506 | 0.455 | 1.238 | 0.266 | 0.603 | 0.247 | 1.470 |
| Smoking status (yes vs. no) | −0.360 | 0.404 | 0.707 | 0.372 | 0.697 | 0.316 | 1.538 |
| Radiotherapy (yes vs. no) | 0.808 | 0.357 | 5.110 | 0.024a | 2.242 | 1.113 | 4.516 |
| Histological type (LAD vs. LSCC) | −0.215 | 0.394 | 0.298 | 0.585 | 0.806 | 0.372 | 1.746 |
| Lymph node metastasis (yes vs. no) | −0.173 | 0.385 | 0.202 | 0.653 | 0.841 | 0.395 | 1.789 |
| Extracranial metastasis (yes vs. no) | −0.273 | 0.410 | 0.443 | 0.506 | 0.761 | 0.340 | 1.701 |
| Brain metastasis (yes vs. no) | −0.261 | 0.396 | 0.436 | 0.509 | 0.770 | 0.355 | 1.672 |
| ECOG (score 1 vs. 2) | −0.876 | 0.328 | 7.133 | 0.008b | 0.416 | 0.219 | 0.792 |
| miR-130a expression (up- vs. downregulation) | −0.406 | 0.450 | 0.812 | 0.368 | 0.666 | 0.276 | 1.611 |
| miR-25 expression (up- vs. downregulation) | −0.723 | 0.487 | 2.200 | 0.138 | 0.485 | 0.187 | 1.261 |
| miR-191* expression (up- vs. downregulation) | −0.825 | 0.389 | 4.509 | 0.034a | 0.438 | 0.205 | 0.938 |
a
P<0.05
b
P<0.01. B, regression coefficient; SE, standard error; Exp(B) odds ratio; miR, microRNA; ECOG, Eastern Cooperative Oncology Group; LAD, lung adenocarcinoma; LSCC, lung squamous cell cancer.